| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/14/2001 | CA1341285C Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines |
| 08/14/2001 | CA1341284C Site-directed mutagenesis modified glycoprotein hormones and methods of use |
| 08/10/2001 | CA2331876A1 Water-soluble ligand-binding proteins and analogs of ligand-gated channels, crystals thereof and their use for screening ligands of ligand-gated ion channels |
| 08/10/2001 | CA2298737A1 2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression |
| 08/09/2001 | WO2001057524A1 Screening method |
| 08/09/2001 | WO2001057278A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human hela cells or other human cervical epithelial cells |
| 08/09/2001 | WO2001057277A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human fetal liver |
| 08/09/2001 | WO2001057276A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human bone marrow |
| 08/09/2001 | WO2001057275A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain |
| 08/09/2001 | WO2001057274A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human heart |
| 08/09/2001 | WO2001057273A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human adult liver |
| 08/09/2001 | WO2001057272A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human placenta |
| 08/09/2001 | WO2001057271A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and bt 474 cells |
| 08/09/2001 | WO2001057270A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and hbl 100 cells |
| 08/09/2001 | WO2001057267A1 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 08/09/2001 | WO2001057266A1 Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057265A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057262A1 Methods and materials relating to neuronal guidance molecule-like (ngm-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057261A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057260A1 Methods and materials relating to scavenger receptor-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057255A1 Methods and materials relating to matrix metalloprotease-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057252A2 Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes |
| 08/09/2001 | WO2001057251A2 Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| 08/09/2001 | WO2001057233A2 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 08/09/2001 | WO2001057226A1 Humanized anti-ccr2 antibodies and methods of use therefor |
| 08/09/2001 | WO2001057225A1 Protein having pge2 synthase activity and use thereof |
| 08/09/2001 | WO2001057222A1 A protease, a gene therefor and the use thereof |
| 08/09/2001 | WO2001057214A2 Human transporter proteins and polynucleotides encoding the same |
| 08/09/2001 | WO2001057213A2 Human bcl-x-like proteins and polynucleotides encoding the same |
| 08/09/2001 | WO2001057210A2 Use of dendroaspin as a vehicle for non-dendroaspin domains |
| 08/09/2001 | WO2001057209A2 Novel family of proteins, called atip, nucleic sequences coding for same and uses thereof |
| 08/09/2001 | WO2001057208A2 Mlp gene, nucleic acids, polypeptides and the utilization thereof |
| 08/09/2001 | WO2001057207A2 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 08/09/2001 | WO2001057206A2 Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| 08/09/2001 | WO2001057205A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr |
| 08/09/2001 | WO2001057194A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 08/09/2001 | WO2001057193A2 Protein c derivatives |
| 08/09/2001 | WO2001057190A2 Novel nucleic acids and polypeptides |
| 08/09/2001 | WO2001057189A2 Fas pathway genes |
| 08/09/2001 | WO2001057188A2 Novel nucleic acids and polypeptides |
| 08/09/2001 | WO2001057187A2 Novel bone marrow nucleic acids and polypeptides |
| 08/09/2001 | WO2001057186A2 Methods and compositions for diagnosis and treatment of cancer based on esf |
| 08/09/2001 | WO2001057184A2 Use of platelet activity modulators for inhibiting complement activation |
| 08/09/2001 | WO2001057182A2 Nucleic acids, proteins, and antibodies |
| 08/09/2001 | WO2001057181A2 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
| 08/09/2001 | WO2001057175A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 08/09/2001 | WO2001057091A1 Soluble, chimeric transcription factors that enter cells to modulate cell differentiation and phenotype |
| 08/09/2001 | WO2001057087A2 High affinity immunoglobulin epsilon receptor beta-subunit-like protein and nucleic acids encoding same |
| 08/09/2001 | WO2001057085A2 G-protein coupled receptors |
| 08/09/2001 | WO2001057084A1 Crystallisation of a glp-1 analogue |
| 08/09/2001 | WO2001057083A1 Methods for promoting growth of bone, ligament, and cartilage using zvegf4 |
| 08/09/2001 | WO2001057082A2 Extraction of growth factors from tissue |
| 08/09/2001 | WO2001057081A2 Narc-1, subtilase-like homologs |
| 08/09/2001 | WO2001057079A2 C1 inhibitor produced in the milk of transgenic mammals |
| 08/09/2001 | WO2001057077A1 Proteins that are specifically expressed or highly overexpressed in tumors and nucleic acids encoding them |
| 08/09/2001 | WO2001057075A2 Virulence genes, proteins, and their use |
| 08/09/2001 | WO2001057074A1 Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection |
| 08/09/2001 | WO2001057072A2 Pharmacologically active antiviral peptides and methods of their use |
| 08/09/2001 | WO2001057071A2 Glycopeptide derivatives having antibiotic activity |
| 08/09/2001 | WO2001057070A1 Melanin-concentrating hormone analogs |
| 08/09/2001 | WO2001057069A2 Targeting peptides |
| 08/09/2001 | WO2001057068A1 Mucin-1 derived antigens and their use in immunotherapy |
| 08/09/2001 | WO2001057067A1 Ligand for vascular endothelial growth factor receptor |
| 08/09/2001 | WO2001057065A2 Combinatorial protein domains |
| 08/09/2001 | WO2001057062A1 Modulation of osf-2 in inflammatory and renal diseases |
| 08/09/2001 | WO2001057061A1 Novel use of ribozymes to block gene expression |
| 08/09/2001 | WO2001057060A1 Bcl-2-like polynucleotides, polypeptides, and antibodies |
| 08/09/2001 | WO2001057059A1 Antisense modulation of survivin expression |
| 08/09/2001 | WO2001056972A1 Method for synthesis of n-[(s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril |
| 08/09/2001 | WO2001056959A1 A substance for the use in a dietary supplementation or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome |
| 08/09/2001 | WO2001056627A1 Medical device coated with antimicrobial peptides |
| 08/09/2001 | WO2001056608A1 Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis |
| 08/09/2001 | WO2001056606A1 Remedies for ophthalmic diseases |
| 08/09/2001 | WO2001056603A1 Cd40-binding apc-activating molecules |
| 08/09/2001 | WO2001056602A2 Cd40 ligand adjuvant for respiratory syncytial virus |
| 08/09/2001 | WO2001056597A1 Pharmaceutical carrier composition for papayne based products |
| 08/09/2001 | WO2001056596A1 Use of lysosomal acid lipase for treating atherosclerosis and related diseases |
| 08/09/2001 | WO2001056595A2 Wound healing compositions and methods using tropoelastin and lysyl oxidase |
| 08/09/2001 | WO2001056594A1 Nasal calcitonin formulations |
| 08/09/2001 | WO2001056593A2 Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke |
| 08/09/2001 | WO2001056592A1 Use of compounds for the regulation of food intake |
| 08/09/2001 | WO2001056591A1 vMIP-II PEPTIDE ANTAGONISTS OF CXCR4 |
| 08/09/2001 | WO2001056590A2 Utilization of protein kinase inhibitor alpha |
| 08/09/2001 | WO2001056579A1 Methods for treating alzheimer's disease |
| 08/09/2001 | WO2001056560A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | WO2001056544A2 Shell-and-core dosage form approaching zero-order drug release |
| 08/09/2001 | WO2001056532A2 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| 08/09/2001 | WO2001056406A1 Improved pediatric formula and methods for providing nutrition and improving tolerance |
| 08/09/2001 | WO2001056405A2 A method for maintaining or improving the synthesis of mucins |
| 08/09/2001 | WO2001056387A1 Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen |
| 08/09/2001 | WO2001032596A8 Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| 08/09/2001 | WO2001021796A3 Gl50 molecules and uses therefor |
| 08/09/2001 | WO2001019966A3 Isolation of muscle-derived stem cells and uses therefor |
| 08/09/2001 | WO2001016312A3 Nucleic acid based modulators of gene expression |
| 08/09/2001 | WO2001010901A3 Antimicrobial histone h1 compositions, kits, and methods of use thereof |
| 08/09/2001 | WO2001008694A3 Direct arterial infiltration for production of vascular pathology |
| 08/09/2001 | WO2001007066A3 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 08/09/2001 | WO2001006988A3 Super-active porcine growth hormone releasing hormone analog |
| 08/09/2001 | WO2001004318A3 Myxoma virus genes for immune modulation |
| 08/09/2001 | WO2001004316A3 Antigenic meningococcal peptides |